Alkermes Plc logo

Alkermes Plc(ALKS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 13 days
PROFIT SINCE LAST BUY
-2.07% ▼
LAST CLOSE
$44.94
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ALKS

11/20/2026: ALKS (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Alkermes Plc is a fully integrated biopharmaceutical company specializing in central nervous system disorders and proprietary drug delivery technologies. The company's main business strengths include established commercial products like LUMRYZ and Aristada, supported by steady manufacturing and royalty streams. Its primary growth story centers on expanding market adoption and label indications for LUMRYZ within the narcolepsy market. Key risks involve revenue concentration in a small product portfolio and intense competition from larger pharmaceutical peers. The stock suits value-oriented or selective growth investors willing to monitor regulatory updates and commercial execution milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitModerate top-line growth driven by key neuroscience products appeals to selective growth seekers.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on a positive Upturn signal driven by regulatory catalysts or earnings beats.
Value investorStrong fitReasonable valuation multiples relative to earnings and strong cash generation attract value-oriented investors.
Dividend investorWeak fitThe company does not pay a dividend, making it unsuitable for income-focused portfolios.
Low-risk investorMixed fitBiotech clinical and regulatory risks introduce volatility that limits appeal for ultra-conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highBiopharmaceutical stocks frequently fluctuate based on clinical updates and regulatory decisions.
Valuation riskMediumShares are reasonably priced relative to earnings, limiting extreme downside valuation risks.
Competition risk (neuroscience and psychiatry)Medium / highIntense competition from large-cap pharma companies threatens product market share.
Business qualityStrongProprietary technology platforms and profitable commercial operations reflect high business quality.
Dividend incomeLow / noneThe absence of a dividend payout means zero income return for shareholders.
Execution riskMediumCommercial success depends on effective execution of product launches and sales strategies.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.76B USD
Price to earnings Ratio -
1Y Target Price 57.74
Price to earnings Ratio -
1Y Target Price 57.74
Volume (30-day avg) 1.7M shares
Beta 0.23
52 Weeks Range 27.00 - 55.67
Updated Date 11/19/2026
52 Weeks Range 27.00 - 55.67
Updated Date 11/19/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.01

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
75.0%
Active BUY / eligible
9 / 12
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -12.41%
Avg. Invested days 34
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ALKS receives a 4-star rating, supported by strong unit economics, solid company fundamentals, and strong analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
ALKS has solid overall fundamentals (4 stars), with solid financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong cash generation (FCF margin 32.5%) and solid profitability (net margin 16.4%) are partially offset by negative earnings growth (-34.2%), negative revenue growth (-5.2%), modest insider ownership of 1.40%.

Financial Health Rating

★★★★★
ALKS's financial health is supported by strong liquidity, including working-capital and asset support (WC/assets 55.7%). Operating efficiency is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is ALKS's strongest growth driver at +18.4% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (-5.2%, negative) and earnings growth (-34.2%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 107.6% and approximately 92.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.40% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 17.40%
Baker Bros Advisors LP 5.96%
Vanguard Portfolio Management, LLC 5.65%
State Street Corp 5.45%
Vanguard Capital Management, LLC 4.47%

Unit Economics (Per $1K Revenue)

★★★★★
ALKS generates approximately $867 of gross profit, $172 of operating income, and $325 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins and strong cash conversion support the rating, although capital efficiency remains solid.

Economic Dimensions

★★★★★
Effective Tax Rate: 17.08%

Quantitative Style Profile

★★★★★
ALKS has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Proprietary Commercial ProductsSales of specialized medicines like LUMRYZ, Aristada, and VIVITROL in the US and international markets.This is the primary engine of direct product revenue and future growth.
Manufacturing and Royalty RevenuesRevenues earned from licensing proprietary formulation technologies and manufacturing products for third-party pharmaceutical partners.Provides stable, recurring cash flows that support ongoing research and development.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-03
When Before Market
Estimate -0.08
Actual 0.09

Profitability

Profit Margin -0.02%
Operating Margin (TTM) 11.46%

Management Effectiveness

Return on Assets (TTM) 3.71%
Return on Equity (TTM) -0.02%

Valuation

Trailing PE -
Forward PE 434.78
Enterprise Value 8.69B
Price to Sales(TTM) 4.43
Enterprise Value 8.69B
Price to Sales(TTM) 4.43
Enterprise Value to Revenue 4.96
Enterprise Value to EBITDA 48.65
Shares Outstanding 168.04M
Shares Floating 155.48M
Shares Outstanding 168.04M
Shares Floating 155.48M
Percent Insiders 1.4
Percent Institutions 107.57

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.